Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

(2017) Zoe Moodie et al.   JOURNAL OF INFECTIOUS DISEASES

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

(2017) Maia A Rabaa et al.   eLife

Vaccination Against Dengue: Challenges and Current Developments

(2016) Bruno Guy et al.   Annual Review of Medicine

Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue exposed individuals

(2016) Sandra Henein et al.   JOURNAL OF INFECTIOUS DISEASES

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination

(2016) Usha K. Nivarthi et al.   JOURNAL OF VIROLOGY

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

(2015) Daniel E. Neafsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers

(2015) G. Fibriansah et al.   SCIENCE

Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display

(2015) Julia C. Frei et al.   VIROLOGY

A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies

(2015) E. N. Gallichotte et al.   mBio

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial

(2015) Paul T. Edlefsen et al.   PLoS Computational Biology

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

(2014) Wanwisa Dejnirattisai et al.   NATURE IMMUNOLOGY

Mark-Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy

(2013) M. Juraska et al.   BIOMETRICS

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Worldwide Spread of Dengue Virus Type 1

(2013) Christian Julián Villabona-Arenas et al.   PLoS One

Influence of evolutionary events on the Indian subcontinent on the phylogeography of dengue type 3 and 4 viruses

(2012) J.A. Patil et al.   INFECTION GENETICS AND EVOLUTION

Structure of a Dengue Virus Envelope Protein Late-Stage Fusion Intermediate

(2012) D. E. Klein et al.   JOURNAL OF VIROLOGY

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

(2012) Arunee Sabchareon et al.   LANCET

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

(2012) R. de Alwis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus

(2011) Joseph JB Cockburn et al.   EMBO JOURNAL

Dengue — Quo tu et quo vadis?

(2011) Rubing Chen et al.   Viruses-Basel

Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape

(2010) Gregory D. Gromowski et al.   VIROLOGY

Phylogeography and evolutionary history of dengue virus type 3

(2008) Josélio M.G. Araújo et al.   INFECTION GENETICS AND EVOLUTION

Molecular genotyping of dengue viruses by phylogenetic analysis of the sequences of individual genes

(2008) C. Klungthong et al.   JOURNAL OF VIROLOGICAL METHODS